Drug Profile
ARCT 154
Alternative Names: ARCT-154; Kostaive; VBC-COV19-154Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics
- Developer Arcturus Therapeutics; Meiji Seika Pharma; Vinbiocare Biotechnology
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 28 Nov 2023 Registered for COVID-2019 infections (Prevention, In adults) in Japan (IM)
- 14 Nov 2023 Arcturus Therapeutics anticipate PDMA approval for COVID-2019 in third quarter of 2024
- 06 Sep 2023 Preregistration for COVID-2019 infections (Prevention, In adults, In the elderly) in European Union (IM)